Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Biologic Therapy/Immunobiology
•
Rheumatology
•
COVID-19
•
General Rheumatology
•
Tocilizumab
•
Biologics
Do you use tocilizumab for the treatment of severe COVID-19 in patients who are on other biologics for rheumatic diseases, such as rituximab?
Related Questions
Are there specific combinations of DMARDs and/or biologics that you avoid due to elevated infection risk or other safety concerns?
How do you identify and treat autoimmune hearing loss?
Do you consider metformin as a disease-modifying adjunct in the management of patients with OA, particularly in those with comorbid metabolic syndrome or type 2 diabetes?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
How do you evaluate and manage brain fog in patients with underlying rheumatic disease?
How do you approach a patient with idiopathic anterior uveitis who has ongoing disease despite adalimumab every two weeks?
What are some situations where a non-prednisone steroid would be more appropriate than prednisone?
When screening for malignancy, do you order CT with contrast (or) both with and without contrast?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
When starting stress dose steroids for patient with primary adrenal insufficiency, how do you decide whether to start hydrocortisone 100 mg every 8 hours versus 50 mg every 6 hours?
